Repligen Technologies and Univercells have partnered to integrate Repligen’s MAVEN® Real Time Glucose Control Platform into Univercells’ scale-X bioreactors to enable continuous monitoring of glucose and lactate during viral vector and vaccine manufacturing. This process analytical technology will improve nutrient control and cell growth estimations without media removal, enhancing bioprocess optimization for adherent cell cultures and supporting advanced therapy development workflows.